Materialise NV (06MA)
XBER 
Summary
06MA Chart
Materialise: Automotive Weakness Is Undermining The Stock
Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Materialise NV (NASDAQ:MTLS ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux, Research Division Troy Donavon Jensen - Cantor Fitzgerald & Co., Research Division Harriet Fried - Unidentified Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2025 Materialise NV Financial Results Conference Call.
Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'
I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and reducing business cyclicality.
Materialise NV Dividends
Materialise NV Earnings
| 23 Oct 2025 (In 2 months) Date | | 0.01 Cons. EPS | - EPS |
| 23 Oct 2025 (In 2 months) Date | | 0.01 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | - Cons. EPS | - EPS |
| 24 Jul 2025 Date | | - Cons. EPS | - EPS |
| 24 Jul 2025 Date | | 0.02 Cons. EPS | 0.01 EPS |
| 23 Oct 2025 (In 2 months) Date | | 0.01 Cons. EPS | - EPS |
| 23 Oct 2025 (In 2 months) Date | | 0.01 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | - Cons. EPS | - EPS |
| 24 Jul 2025 Date | | - Cons. EPS | - EPS |
| 24 Jul 2025 Date | | 0.02 Cons. EPS | 0.01 EPS |
Materialise NV (06MA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Materialise NV ever had a stock split?
Materialise NV Profile
| Software - Application Industry | Technology Sector | Brigitte de Vet-Veithen CEO | XBER Exchange | US57667T1007 ISIN |
| BE Country | 488 Employees | - Last Dividend | - Last Split | 25 Jun 2014 IPO Date |
Overview
Materialise NV stands as a pivotal provider in the realms of additive manufacturing and medical software, coupled with 3D printing services, which spans across the Americas, Europe and Africa, and the Asia-Pacific. With its operational foundation laid down in 1990 and headquartered in Leuven, Belgium, Materialise NV has compartmentalized its expertise into three primary segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The company has fostered collaborative agreements with eminent entities like Zimmer Biomet Holdings, Inc., Encore Medical, L.P., DePuy Synthes Companies of Johnson & Johnson, and several others, demonstrating its industry significance and widespread trust. This extensive collaboration network underscores Materialise NV's influential role in advancing 3D printing applications within both industrial and medical frameworks.
Products and Services
- Materialise Software
- Materialise Medical
- Materialise Manufacturing
Facilitates and enhances 3D printing operations through a comprehensive suite of software programs and platforms. This segment bridges various 3D printers with numerous software applications and capturing technologies, including CAD/CAM packages and 3D scanners. Its target clientele encompasses 3D printing machine manufacturers, production companies, and contract manufacturers across industries such as automotive, aerospace, consumer goods, and hearing aids, in addition to 3D printing service bureaus. Distribution is achieved via a direct sales force, a dedicated website, and through third-party resellers.
Focuses on delivering medical software that facilitates the analysis, planning, and engineering based on medical imaging, as well as the patient-specific design and printing of surgical devices and implants. This segment's offerings are primarily directed at medical device companies, hospitals, universities, research institutes, and industrial entities. Distribution is steered through direct sales efforts, the company's website, and Picture Archiving Communication Systems (PACS), underscoring Materialise's pivotal role in innovating medical procedures and patient care.
Provides 3D printing services alongside design and engineering services, catering to the rapid prototyping and additive manufacturing needs of production parts for industrial and commercial clients. This segment encapsulates Materialise NV's direct contribution to the manufacturing industry, showcasing its capabilities in turning conceptual designs into tangible, high-quality parts and products through state-of-the-art 3D printing technologies.
Contact Information
